Literature DB >> 2411826

Elevated levels of interferon-induced 2'-5' oligoadenylate synthetase in generalized persistent lymphadenopathy and the acquired immunodeficiency syndrome.

S E Read, B R Williams, R A Coates, W K Evans, M M Fanning, M B Garvey, F A Shepherd.   

Abstract

The levels of the 2'-5' oligoadenylate enzyme synthetase in extracts of peripheral blood mononuclear cells from individuals with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC) were measured and compared with synthetase levels in peripheral blood mononuclear cells (PBMs) from healthy heterosexual and homosexual controls. The mean basal synthetase level in heterosexual and homosexual controls was 14 +/- 13 and 12 +/- 9 pmol per hr/10(5) PBMs, respectively. Thirteen individuals with AIDS had a mean basal level of 129 +/- 75 pmol. Serial levels were persistently elevated in six of these individuals over a one- to 10-month period. Twelve of the 13 individuals had antibodies to human T cell lymphotrophic virus-III/lymphadenopathy-associated virus (HTLV-III/LAV). Thirty-three individuals with ARC had a mean basal synthetase level of 68 +/- 84 pmol. Thirty-two of the 33 had antibodies to HTLV-III/LAV. Eleven (33%) have had consistently normal synthetase levels (less than 2 SD above the mean for the homosexual controls, i.e., 30 pmol) over a three- to nine-month follow-up period. Fourteen (42%) had persistently elevated levels over the same period; four (29%) of these developed AIDS during the follow-up period. Eight have had fluctuating levels but have remained clinically well. These studies suggest that persistently elevated synthetase levels in individuals with ARC and antibodies to HTLV-III/LAV indicate progressive virus-induced disease activity. Elevated synthetase levels may be an important prognostic indicator of increased risk of progression to AIDS.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411826     DOI: 10.1093/infdis/152.3.466

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Increased activity of oligo-2',5'-adenylate synthetase in Down's syndrome and epilepsy.

Authors:  N Fujii; K Oguma; M Fujii; R Fukatsu; N Takahata; M Kitabatake
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

2.  Downregulation of interferon alpha but not gamma receptor expression in vivo in the acquired immunodeficiency syndrome.

Authors:  A S Lau; S E Read; B R Williams
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

3.  Endotoxin induction of tumor necrosis factor is enhanced by acid-labile interferon-alpha in acquired immunodeficiency syndrome.

Authors:  A S Lau; J F Livesey
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

4.  Detection of elevated levels of 2-5A synthetase in serum from children with various infectious diseases.

Authors:  H Sugino; I Mitani; M Koike; T Kodama; J Sokawa; H Sawai; K Ishibashi; M Itoh; S Watanabe; Y Sokawa
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

5.  Cyclosporine-induced deterioration in patients with AIDS.

Authors:  A Phillips; M A Wainberg; R Coates; M Klein; A Rachlis; S Read; F Shepherd; H Vellend; S Walmsley; P Halloran
Journal:  CMAJ       Date:  1989-06-15       Impact factor: 8.262

6.  Effect of alpha interferon (IFN-alpha) on 2'-5' oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: relationship to the antiviral effect of IFN-alpha.

Authors:  J M Pawlotsky; A G Hovanessian; F Roudot-Thoraval; N Robert; M Bouvier; G Babany; J Duval; D Dhumeaux
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Elevated levels of innate immune modulators in lymph nodes and blood are associated with more-rapid disease progression in simian immunodeficiency virus-infected monkeys.

Authors:  Andre Durudas; Jeffrey M Milush; Hui-Ling Chen; Jessica C Engram; Guido Silvestri; Donald L Sodora
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103

8.  Activation of interferon-regulated, dsRNA-dependent enzymes by human immunodeficiency virus-1 leader RNA.

Authors:  D N SenGupta; R H Silverman
Journal:  Nucleic Acids Res       Date:  1989-02-11       Impact factor: 16.971

9.  Combination chemotherapy and alpha-interferon in the treatment of Kaposi's sarcoma associated with acquired immune deficiency syndrome.

Authors:  F A Shepherd; W K Evans; B Garvey; S E Read; M Klein; M M Fanning; R Coates
Journal:  CMAJ       Date:  1988-10-01       Impact factor: 8.262

10.  Clinical significance of serum 2,5-oligoadenylate synthetase and soluble interleukin-2 receptor in hemophiliacs positive and negative for human immunodeficiency virus type 1.

Authors:  J Matsuda; M Gotoh; K Gohchi; M Tsukamoto; N Saitoh; T Kinoshita
Journal:  Clin Diagn Lab Immunol       Date:  1994-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.